Citius Oncology Inc (CTOR) FinancialsCTORCitius Oncology Inc

Evaluating the bottom line, Citius Oncology Inc maintains a gross margin of 67.07%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -583.54%, while the net margin is -597.40%. These profitability ratios, combined with a Return on Equity (ROE) of -126.58%, provide a clear picture of how effectively CTOR converts its operational activities into shareholder value.

In the context of the broader market, CTOR competes directly with industry leaders such as CNTB and XLO. With a market capitalization of $46.50M, it holds a significant position in the sector. When comparing efficiency, CTOR's gross margin of 67.07% stands against CNTB's 100.00% and XLO's 100.00%. Such benchmarking helps identify whether Citius Oncology Inc is trading at a premium or discount relative to its financial performance.

Citius Oncology has shown significant revenue growth, achieving $3.94 million in Q1 2026 and $1.67 million in Q2 2026, with a gross margin of 80.27% in Q2 2026, indicating strong profitability on sales despite overall losses.